ViroGates A/SAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 1.466.000 | 60.083.000 | 41.407.000 | 33.526.000 | 14.859.000 | 9.878.000 | 16.027.000 | 12.208.000 | 26.297.000 |
| Omsætningsaktiver i alt | — | — | — | — | 19.838.000 | 17.310.000 | 24.379.000 | 17.478.000 | 30.403.000 |
| Anlægsaktiver i alt | 350.000 | 228.000 | 715.000 | 603.000 | 391.000 | 229.000 | 177.000 | — | — |
| Aktiver i alt | 4.977.000 | 63.424.000 | 45.157.000 | 38.246.000 | 20.229.000 | 17.539.000 | 24.555.000 | 17.660.000 | 30.589.000 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 1.979.000 | 2.412.000 | 2.942.000 | 5.912.000 | 3.803.000 | 1.451.000 | 2.248.000 | 2.591.000 | 7.856.000 |
| Langfristede gældsforpligtelser | — | — | — | 1.020.000 | — | — | 5.300.000 | 4.273.000 | 3.330.000 |
| Gældsforpligtelser i alt | 1.979.000 | 2.412.000 | 2.942.000 | 6.932.000 | 3.803.000 | 1.451.000 | 7.548.000 | 6.864.000 | 11.186.000 |
| Selskabskapital | 2.210.000 | 3.034.000 | 3.034.000 | 3.125.000 | 3.170.000 | 3.350.000 | 6.448.000 | 7.737.000 | 9.284.000 |
| Overført resultat | 788.000 | 57.978.000 | 39.181.000 | 28.189.000 | 13.256.000 | 12.738.000 | 10.560.000 | 3.058.000 | 10.119.000 |
| Årets resultat | -5.987.000 | -16.986.000 | -18.797.000 | -18.736.000 | -17.663.000 | -9.646.000 | -12.096.000 | -14.345.000 | -10.397.000 |
| Egenkapital i alt | 2.998.000 | 61.012.000 | 42.215.000 | 31.314.000 | 16.426.000 | 16.088.000 | 17.007.000 | 10.795.000 | 19.403.000 |
| Resultatopgørelse | |||||||||
| Omsætning | 2.441.000 | 3.315.000 | 3.582.000 | 5.354.000 | 7.656.000 | 10.151.000 | 5.582.000 | 4.897.000 | 5.307.000 |
| Bruttofortjeneste | -4.263.000 | -12.119.000 | 3.198.000 | 4.190.000 | — | — | 5.805.000 | 4.809.000 | 6.621.000 |
| Resultat af primær drift | -7.690.000 | -18.102.000 | -19.723.000 | -19.729.000 | -18.790.000 | -10.845.000 | -12.565.000 | -14.560.000 | -10.472.000 |
| EBITDA | -7.571.000 | -17.977.000 | — | — | — | — | — | — | — |
| Resultat før skat | -7.697.000 | -18.916.000 | -20.009.000 | -19.982.000 | -18.965.000 | -10.876.000 | -13.090.000 | -15.180.000 | -11.229.000 |
| Årets resultat | -5.987.000 | -16.986.000 | -18.797.000 | -18.736.000 | -17.663.000 | -9.646.000 | -12.096.000 | -14.345.000 | -10.397.000 |
| Personaleomkostninger | 3.308.000 | 5.858.000 | — | — | — | — | — | — | — |
| Af- og nedskrivninger | 119.000 | 125.000 | — | — | — | — | — | — | — |
| Andre nøgletal | |||||||||
| Ansatte | 4 | 6 | 9 | 11 | 13 | 9 | 10 | 10 | 7 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Investment highlights Vast potential 26.3 DKKm +20 countries Supplied with suPARnostic® In preventive health and longevity Cash end-of-period During 2025, customer purchase orders for suPAR- The preventive health and longevity segment, in which 26.3 DKKm in cash and cash equivalents by the end nostic® spanned more than 20 countries globally. suPARnostic® is positioned to monitor, manage, and of 2025, including proceeds from the directed rights optimize personal health and well-being, represents issue completed in November 2025. a substantial opportunity for ViroGates. In 2025, the +1,100 peer- Company has actively engaged with relevant com- munities at conferences, advanced a proof-of-con- cept for its point-of-care solution to wellness settings, 20 recurring reviewed articles and continued building recurring demand from health and preventive care customers. customers The current addressable market extends beyond tra- On PubMed ditional hospital laboratories into clinical lab services, By the end of 2025, a total of 1,175 peer-reviewed articles on health clinics, and specialty wellness providers, where suPARhadbeenpublished,reflectingsustainedacademicand In clinical routine and research suPARnostic® can be integrated into routine health clinicalinterest. suPARiswidelyresearchedacrossacutecare, 20 customers across Europe, North America, and ROW assessments and longitudinal health monitoring. This disease-specific specialties, prevention, and healthy aging. who have placed at l
Uddrag af ledelsesberetningen i den seneste årsrapport.